BridgeMD
Study of Tumor Alterations Responsive to Targeting Receptor Kinases-2
EU CTIS ID: 2023-505034-10-00
What this study is testing
To determine the objective response rate of entrectinib, as assessed by BICR, in each patient population basket of solid tumors that harbor an NTRK1/2/3, ROS1, or ALK gene rearrangement
- Therapeutic exploratory (Phase II)
A plain-language read of the study's public EU CTIS listing. The study team confirms the details.
Who can take part
You may be able to join if
- Histologically or cytologically confirmed diagnosis of locally advanced or metastatic solid tumor that harbors an NTRK1/2/3, ROS1, or ALK gene rearrangement that is predicted to translate into a fusion protein with a functional TrkA/B/C, ROS1, or ALK kinase domain, respectively, without a concomitant second oncodriver (e.g., EGFR, KRAS), as determined by Foundation Medicine, Inc. or by any nucleic acid-based diagnostic testing method (please refer to Section 5.1) performed at a local CLIA-certified or equivalently-accredited diagnostic laboratory. These are patients for whom no alternative effective standard therapy is available or for whom standard therapy is considered unsuitable or intolerable. Note: Patients diagnosed with anaplastic large cell lymphoma (ALCL) harboring a gene rearrangement of interest are no longer eligible.
- Eastern Cooperative Oncology Group (ECOG) performance status ≤ 2 and minimum life expectancy of at least 4 weeks.
- Adequate liver function as defined by the following criteria: -Serum aspartate transaminase (AST; serum glutamic oxaloacetic transaminase (SGOT)) and serum alanine transaminase (ALT; serum glutamic pyruvic transaminase (SGPT)) ≤ 3.0 × upper limit of normal (ULN); ≤ 5.0 × ULN if liver metastases are present -Total serum bilirubin ≤ 2.0 × ULN; patients with a known history of Gilbert's syndrome and/or isolated elevations of indirect bilirubin are eligible
- Women patients of childbearing potential: • Must have a negative serum pregnancy test during screening and must not be breastfeeding or intending to become pregnant during the study • Must agree to remain abstinent or use single or combined contraception methods that result in a failure rate of < 1% per year prior to entering into the study and for 5 weeks following the last dose of study drug • Allowance for locally recognized adequate methods of contraception • Must agree to refrain from donating eggs during the same period -Oral contraceptives and intrauterine hormone releasing systems (IUSs) used by female patients must be combined with a barrier method. Male patients with female partners of childbearing potential: • Must agree to use highly effective contraception during the study and for 3 months following the last dose of study drug. • Requirement for male patients to abstain from donating sperm during the study and for 3 months after study.
- Ability to swallow entrectinib intact without chewing, crushing, or opening the capsules. Please refer to the Section 5.2.2 of the Protocol for the complete list of the Inclusion criteria
- For patients enrolled via local molecular testing, an archival or fresh tumor tissue (unless medically contraindicated) is required to be submitted for independent central molecular testing at Foundation Medicine, Inc. 1. or to the alternative, approved central laboratory for that region.
You likely can't join if
- Current participation in another therapeutic clinical trial.
- Peripheral sensory neuropathy Grade ≥ 2.
- Known active infections that would interfere with the assessment of safety or efficacy of entrectinib (bacterial, fungal, or viral) with the exceptions of human Immunodeficiency virus (HIV), hepatitis B virus (HBV), and hepatitis C virus (HCV) infections, as noted below: – HIV positivity, only if patients meet any of the following criteria: Patients with a CD4+ T-cell count of <350 cells/μL Patients with a detectable HIV viral load Patients with a history of an opportunistic infection within the past 12 months Patients who are on stable antiretroviral therapy for < 4 weeks – Active HBV infection (chronic or acute; defined as having a positive hepatitis B surface antigen [HBsAg] test), with the following exception: Patients with past HBV infection or resolved HBV infection (defined as the presence of hepatitis B core antibody [HBcAb] and absence of HBsAg) if they are negative for HBV DNA – HCV antibody (HCV Ab) positivity, with the following exceptions: Patients who are HCV Ab-positive but HCV RNA-negative due to prior treatment or natural resolution are eligible Patients with untreated HCV if the HCV is stable, the patient is not at risk for hepatic decompensation, and the intended treatment is not expected to exacerbate the HCV infection Patients on concurrent HCV treatment if they have HCV below the limit of quantification
- Active gastrointestinal disease (e.g., Crohn's disease, ulcerative colitis, or short gut syndrome) or other malabsorption syndromes that would reasonably impact drug absorption.
- Known interstitial lung disease, interstitial fibrosis, or history of tyrosine kinase inhibitor-induced pneumonitis. Note: Radiation-induced lung disorders are not included in this exclusion criterion.
- Other severe acute or chronic medical or psychiatric condition or laboratory abnormality that may increase the risk associated with study participation or study drug administration or may interfere with the interpretation of study results and, in the judgment of the Investigator, would make the patient inappropriate for entry into this study or could compromise protocol objectives in the opinion of the Investigator and/or the Sponsor
See the full eligibility criteria
Who can join
- Histologically or cytologically confirmed diagnosis of locally advanced or metastatic solid tumor that harbors an NTRK1/2/3, ROS1, or ALK gene rearrangement that is predicted to translate into a fusion protein with a functional TrkA/B/C, ROS1, or ALK kinase domain, respectively, without a concomitant second oncodriver (e.g., EGFR, KRAS), as determined by Foundation Medicine, Inc. or by any nucleic acid-based diagnostic testing method (please refer to Section 5.1) performed at a local CLIA-certified or equivalently-accredited diagnostic laboratory. These are patients for whom no alternative effective standard therapy is available or for whom standard therapy is considered unsuitable or intolerable. Note: Patients diagnosed with anaplastic large cell lymphoma (ALCL) harboring a gene rearrangement of interest are no longer eligible.
- Eastern Cooperative Oncology Group (ECOG) performance status ≤ 2 and minimum life expectancy of at least 4 weeks.
- Adequate liver function as defined by the following criteria: -Serum aspartate transaminase (AST; serum glutamic oxaloacetic transaminase (SGOT)) and serum alanine transaminase (ALT; serum glutamic pyruvic transaminase (SGPT)) ≤ 3.0 × upper limit of normal (ULN); ≤ 5.0 × ULN if liver metastases are present -Total serum bilirubin ≤ 2.0 × ULN; patients with a known history of Gilbert's syndrome and/or isolated elevations of indirect bilirubin are eligible
- Women patients of childbearing potential: • Must have a negative serum pregnancy test during screening and must not be breastfeeding or intending to become pregnant during the study • Must agree to remain abstinent or use single or combined contraception methods that result in a failure rate of < 1% per year prior to entering into the study and for 5 weeks following the last dose of study drug • Allowance for locally recognized adequate methods of contraception • Must agree to refrain from donating eggs during the same period -Oral contraceptives and intrauterine hormone releasing systems (IUSs) used by female patients must be combined with a barrier method. Male patients with female partners of childbearing potential: • Must agree to use highly effective contraception during the study and for 3 months following the last dose of study drug. • Requirement for male patients to abstain from donating sperm during the study and for 3 months after study.
- Ability to swallow entrectinib intact without chewing, crushing, or opening the capsules. Please refer to the Section 5.2.2 of the Protocol for the complete list of the Inclusion criteria
- For patients enrolled via local molecular testing, an archival or fresh tumor tissue (unless medically contraindicated) is required to be submitted for independent central molecular testing at Foundation Medicine, Inc. 1. or to the alternative, approved central laboratory for that region.
- Measurable disease as assessed locally using RECIST v1.1. Note: Patients with non-measurable disease (evaluable disease only) will be eligible for enrollment in the "non-evaluable for the primary endpoint" basket and will mainly contribute to assessment of safety, PK, and other secondary endpoints.
- Patients with CNS involvement, including leptomeningeal carcinomatosis, which is either asymptomatic or previouslytreated and controlled, are allowed. The use of seizure prophylaxis is allowed as long as patients are taking non-enzyme-inducing anti-epileptic drugs (non-EIAEDs).
- Prior anticancer therapy is allowed (excluding approved or investigational Trk, ROS1, or ALK (non-NSCLC patients only) inhibitors in patients who have tumors that harbor those respective gene rearrangements). Note: The ALK basket is closed to enrolment.
- At least 2 weeks or 5 half-lives, whichever is shorter, must have elapsed after prior chemotherapy or small molecule targeted therapy, respectively, at the time of the start of entrectinib treatment. Note: For targeted therapies, there must be no signs of disease flare or accelerated disease progression after treatment discontinuation.
- At least 4 weeks must have elapsed since completion of antibody-directed therapy at the time of the start of Entrectinib treatment.
- Prior radiotherapy is allowed if more than 14 days have elapsed since the end of treatment. Patients who received brain irradiation must have completed whole brain radiotherapy at least 14 days prior and/or stereotactic radiosurgery at least 7 days prior to the start of entrectinib treatment.
- Age ≥ 18 years
What rules you out
- Current participation in another therapeutic clinical trial.
- Peripheral sensory neuropathy Grade ≥ 2.
- Known active infections that would interfere with the assessment of safety or efficacy of entrectinib (bacterial, fungal, or viral) with the exceptions of human Immunodeficiency virus (HIV), hepatitis B virus (HBV), and hepatitis C virus (HCV) infections, as noted below: – HIV positivity, only if patients meet any of the following criteria: Patients with a CD4+ T-cell count of <350 cells/μL Patients with a detectable HIV viral load Patients with a history of an opportunistic infection within the past 12 months Patients who are on stable antiretroviral therapy for < 4 weeks – Active HBV infection (chronic or acute; defined as having a positive hepatitis B surface antigen [HBsAg] test), with the following exception: Patients with past HBV infection or resolved HBV infection (defined as the presence of hepatitis B core antibody [HBcAb] and absence of HBsAg) if they are negative for HBV DNA – HCV antibody (HCV Ab) positivity, with the following exceptions: Patients who are HCV Ab-positive but HCV RNA-negative due to prior treatment or natural resolution are eligible Patients with untreated HCV if the HCV is stable, the patient is not at risk for hepatic decompensation, and the intended treatment is not expected to exacerbate the HCV infection Patients on concurrent HCV treatment if they have HCV below the limit of quantification
- Active gastrointestinal disease (e.g., Crohn's disease, ulcerative colitis, or short gut syndrome) or other malabsorption syndromes that would reasonably impact drug absorption.
- Known interstitial lung disease, interstitial fibrosis, or history of tyrosine kinase inhibitor-induced pneumonitis. Note: Radiation-induced lung disorders are not included in this exclusion criterion.
- Other severe acute or chronic medical or psychiatric condition or laboratory abnormality that may increase the risk associated with study participation or study drug administration or may interfere with the interpretation of study results and, in the judgment of the Investigator, would make the patient inappropriate for entry into this study or could compromise protocol objectives in the opinion of the Investigator and/or the Sponsor
- Prior treatment with approved or investigational Trk, ROS1, or ALK inhibitors in patients who have tumors that harbor those respective gene rearrangements. Note: In cases where the patient was intolerant to prior Trk, ROS1, or ALK inhibitors, please discuss with the Sponsor. In addition, prior treatment with crizotinib is permitted ONLY in ALK- or ROS1-rearranged NSCLC patients presenting with CNS-only progression. Other ALK or ROS1 inhibitors are prohibited in that scenario.
- History of other previous cancer that would interfere with the determination of safety or efficacy of entrectinib with respect to the qualifying solid tumor malignancy. Note: Patients presenting with dual primary cancers may enroll in the "non-evaluable for the primary endpoint" basket if at least one of the cancers harbor an NTRK1/2/3, ROS1, or ALK gene rearrangement as per Inclusion Criterion 1.
- Familial or personal history of congenital bone disorders or bone metabolism alterations
- Incomplete recovery from any surgery prior to the start of entrectinib treatment that would interfere with the determination of safety or efficacy of entrectinib.
- Any condition (in the past 3 months) that would interfere with the determination of safety or efficacy of entrectinib: myocardial infarction, unstable angina, coronary/peripheral artery bypass graft, cerebrovascular accident or transient ischemic attack, stroke, symptomatic bradycardia, or uncontrolled arrhythmias requiring medication.
- History of recent (within the past 3 months) symptomatic congestive heart failure or ejection fraction 50% observed during screening for the study
- History of non-pharmacologically induced prolonged QTc interval (e.g., repeated demonstration of a QTc interval > 450 milliseconds from ECGs performed at least 24 hours apart).
- History of additional risk factors for torsades de pointes (e.g., family history of long QT syndrome).
The study team makes the final eligibility decision.
Where it's taking place
- United States
- United Kingdom
- Singapore
- China
- Taiwan
- Hong Kong
- Korea, Republic of
- Australia
- Japan
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 65+ years, 18-64 years. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include United States; United Kingdom; Singapore; China; Taiwan; Hong Kong and 3 more location(s). Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from EU CTIS; the study team decides eligibility.